Objective: The purpose of the study is to develop a high sensitive and short runtime method to quantify oseltamivir phosphate impurities (C and D) and characterization of oseltamivir phosphate API. Methods: The active pharmaceutical ingredient (API) characterization was done using spectroscopic techniques such as mass, infrared spectroscopy (IR), differential scanning calorimetry (DSC), proton nuclear magnetic resonance (H-NMR), phosphorus nuclear magnetic resonance (P-NMR), carbon-13 nuclear magnetic resonance (C13-NMR), and two-dimensional nuclear magnetic resonance (2D-NMR). The impurities (C and D) quantification was done using ACQUITY UPLC BEH C18- 100 mm × 2.1 mm, 1.7 μm column connected to ACQUITY UPLC with PDA detector. The optimized chromatographic conditions were achieved at 0.3 mL/min flow rate using gradient system with 0.1% orthophosphoric acid in water and acetonitrile as mobile phase. Both impurities are measured at λmax 210 nm at 30°C column temperature. Results: The finalized method has given good peak shape and resolution for impurity-C and impurity-D at Rt = 3.39 and 4.33 min, respectively, and the quantification method is linear and its r2 > 0.999 as a correlation coefficient. The recoveries of impurity-C and impurity-D were found in the range of 100±15% at 0.05, 0.1, and 0.15 and limit of quantitation (LOQ) % concentration levels. The other validation parameters such as specificity, system precision, sensitivity, method precision, ruggedness, robustness, and solution stability were established for this method, and the results are satisfactory as per International Council for Harmonization (ICHQ2). Conclusion: The characterization data confirm the structure of oseltamivir phosphate active pharmaceutical ingredient (API). The validated method shall be used for regular analysis as well as release analysis in quality control (QC).
To evaluate the characterization of Famotidine API (active pharmaceutical ingredient) and develop the accurate, precise, linear ultra-performance liquid chromatographic (UPLC) method for quantitating determination of organic impurities (Impurity-A, Impurity-B, and Impurity-C) in Famotidine API, pharmaceutical dosage forms and the method has been validated as per international council of harmonization (ICH) guidelines. The Famotidine API characterization was done by using spectroscopic techniques such as mass, infrared spectroscopy (IR), differential scanning calorimetry (DSC), proton nuclear magnetic resonance (1H-NMR), Carbon-13 nuclear magnetic resonance (C13-NMR), and two-dimensional nuclear magnetic resonance (2D-NMR). The organic impurities (A, B, and C) quantification was done using ACQUITY UPLC CSH C18- 100 mm × 2.1 mm, 1.7 μm column connected to ACQUITY UPLC with PDA detector. The optimized chromatographic conditions were achieved at 0.3 mL/min flow rate using a gradient system with 0.1% Tri fluoro acetic acid in water acetonitrile and Methanol as mobile phase. Three organic impurities are measured at λmax 260 nm at 45°C column temperature. Famotidine structure was confirmed by the appraised complete characterization data. The coefficient of correlation (r2) for the Impurity-A, Impurity-B, and Impurity-C was obtained not less than 0.99. The limit of detection (LOD) obtained 0.12 µg/mL and the limit of quantification (LOQ) obtained 0.4 µg/mL for each impurity concerning Famotidine test concentration. The method was fully validated as precision, accuracy, LOQ precision, LOQ accuracy, ruggedness, and robustness complying with FDA, ICH, AOAC, and European medicines agency (EMEA) guidelines. The characterization study and the proposed UPLC method were specific, accurate, precise, linear, rugged, and robust for the determination of the three organic impurities in Famotidine API and it can be implemented for its intended use in pharmaceutical industries.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.